PRESS RELEASE
News
-
-
PRESS RELEASE
Original-Research: Sernova Biotherapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates BUY recommendation for Sernova Biotherapeutics Inc. (ISIN: CA81732W1041) with a target price of CAD1.90. FDA IND application for Cell Pouch in hypothyroidism patients submitted -
-
PRESS RELEASE
Stillwater Announces Closing of Flow-Through Private Placement for the Kluane Critical Minerals Project in Yukon, Canada
Stillwater Critical Minerals Corp. announces successful closure of non-brokered private placement, raising $375,010 for exploration activities in Canada and Yukon Territory -
PRESS RELEASE
Athena Gold Corporation's Form S-4 Registration Statement Has Been Declared Effective By The SEC For The Proposed Merger
Athena Gold Corp announces SEC approval for merger with Nova Athena, scheduling shareholder meeting virtually via Zoom on March 27, 2025. Merger to reduce compliance costs and enhance market access -
PRESS RELEASE
Silver Tiger Intersects 3.0 meters of 1,526.3 g/t Silver Equivalent Within 17.3 meters of 309.0 g/t Silver Equivalent in the Sulfide Zone from Underground Drilling Station
Silver Tiger Metals Inc. reports high-grade assay results from underground drilling campaign at El Tigre Project in Mexico. Exploration targets Vein, Sulfide & Shale Zones -
PRESS RELEASE
BluSky Carbon Announces Closing of US$500,000 Secured Debenture Financing and Announces Private Placement Financings
BluSky Carbon Inc. completes non-brokered private placements of secured and unsecured debentures, announces future private placement offerings to fund business development and working capital -
PRESS RELEASE
Mawson Finland Limited Reports First Results for 2025 Winter Drilling Program Significant Step-out Extensions in Rajapalot and New Downhole-EM Survey Results
Mawson Finland Limited announces positive results from the 2025 drilling season at Rajapalot gold-cobalt project in Finland, demonstrating potential mineralization and successful geophysical surveys -
-
PRESS RELEASE
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
NanoViricides, Inc. declares readiness to combat bird flu with broad-spectrum antiviral drug NV-387. Scientific discussion on virus mutations and potential effectiveness against H5N1. Focus on Trump administration's response
